Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. The Company's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2-agonist, and fluticasone furoate, an inhaled corticosteroid, delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium, a long-acting muscarinic antagonist, and vilanterol (VI), a long-acting beta2-agonist for the treatment of chronic obstructive pulmonary diseases.

Company Growth (employees)
Type
Public
HQ
Brisbane, US
Founded
1996
Size (employees)
14 (est)
Website
inva.com
Innoviva was founded in 1996 and is headquartered in Brisbane, US

Innoviva Office Locations

Innoviva has an office in Brisbane
Brisbane, US (HQ)
500 2000 Sierra Point Pkwy

Innoviva Financials and Metrics

Innoviva Financials

Innoviva's revenue was reported to be $40.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

40.5 m

Net income (Q1, 2017)

16.8 m

EBIT (Q1, 2017)

29.3 m

Market capitalization (16-Oct-2017)

1.5 b

Closing share price (16-Oct-2017)

13.8

Cash (31-Mar-2017)

159.8 m
Innoviva's current market capitalization is $1.5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.8 m8.4 m53.9 m133.6 m

Revenue growth, %

77%540%148%

R&D expense

1.4 m

General and administrative expense

23.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

934 k999 k6.9 m10.7 m13.6 m24.2 m32.5 m33.3 m40.5 m

R&D expense

2.1 m1.9 m712 k638 k547 k392 k370 k286 k354 k

General and administrative expense

8.6 m8.6 m5.4 m4.9 m4.6 m6.3 m6.2 m5.1 m10.8 m

Operating expense total

10.7 m10.5 m6.2 m5.5 m5.1 m6.6 m6.6 m5.4 m11.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

143.5 m96.8 m159.2 m118 m

Inventories

10.4 m814 k766 k

Current Assets

483.2 m252.2 m214.3 m198 m

PP&E

10.2 m324 k221 k368 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

208.1 m119.6 m141.2 m149.6 m78.7 m151.8 m112.9 m93.2 m159.8 m

Current Assets

353.2 m273.5 m262.4 m244 m223.8 m196.7 m190.4 m186.1 m214.4 m

PP&E

64 k303 k276 k248 k193 k174 k381 k328 k

Total Assets

605.6 m553.7 m488.7 m462.1 m437.6 m387.8 m378.1 m370.5 m391.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(170.7 m)(168.5 m)(18.8 m)59.5 m

Depreciation and Amortization

8.2 m12.2 m13.9 m14 m

Inventories

(3.1 m)(1.9 m)

Accounts Payable

1.6 m(7.7 m)818 k(690 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(63.6 m)(21.3 m)(10.7 m)(7.8 m)(4.6 m)4.4 m14.6 m15 m16.8 m

Accounts Payable

1.8 m573 k1 m462 k154 k576 k137 k528 k2.3 m
USDY, 2017

Revenue/Employee

2.9 m

Financial Leverage

-1.2 x
Show all financial metrics

Innoviva Operating Metrics

FY, 2016

Patents Issued

33
Show all operating metrics

Innoviva Market Value History

Traffic Overview of Innoviva

Innoviva Company Life and Culture

You may also be interested in